Risperdal News
Although Risperdal received FDA approval to treat the symptoms of schizophrenia, recent news about the drug suggests that it may not be the safest form of treatment available. In 2003, Risperdal manufacturer Janssen Pharmaceutica Products announced that they would be contacting thousands of doctors warning of a possible link between Risperdal use and stroke in elderly patients.
The 2003 announcement followed a 2002 warning by Janssen to Canadian physicians. The 2002 warning reported 37 stroke or stroke-like events, including 16 deaths. In 2004, Janssen sent a letter to the healthcare community explaining the potential health risks associated with Risperdal. This letter followed extensive criticism by the medical community and the public that Janssen was deceptive in their advertising and promotion of the drug.
Risperdal has been prescribed for more than eight years to over 10 million people worldwide. It is the most popular drug used to treat schizophrenia, but several high-profile lawsuits have demonstrated the health risks associated with Risperdal. The drug is particularly hazardous to children and the elderly. Such risks prompted the FDA to become involved and require warning labels on Risperdal and other antipsychotic drugs.
Risperdal News Stories:
Teva Receives First U.S. Approval For Generic Risperdal(R) Tablets; Commences Commercial Launch
Main Category: Pharma Industry / Biotech Industry Also Included In: Regulatory Affairs / Drug Approvals Article Date: 03 Jul 2008 Teva Pharmaceutical Industries Ltd.
Teva Granted Final Approval of Risperidone ANDA; Launches with 180-Day Exclusivity
On Monday, Teva announced that the FDA granted final approval to its ANDA for generic Risperdal tablets.
The FDA has approved the first generic Risperdal to treat schizophrenia, bipolar disorder, and other psychiatric conditions.
FDA Approves First Generic Risperidone to Treat Psychiatric Conditions
The U.S. Food and Drug Administration today approved the first generic versions of Risperdal tablets.
Assessment of strategies for switching patients from olanzapine to...
In clinical practice, physicians often need to change the antipsychotic medications they give to patients because of an inadequate response or the presence of unacceptable or unsafe side effects.
David Anderson: The scandal of dementia drugs must be addressed
That antipsychotic drugs are overprescribed to people with dementia is a symptom of our neglect.
Looking after patients with dementia
Carrying on about the dementia saga, the plot thickens. I see that the government's "new" dementia strategy includes plans to assign every patient with dementia a - dementia care advisor' who can be their ...
Review ordered for dementia drugs
The government today ordered an immediate review into the use of antipsychotic drugs to calm the behaviour of people with dementia.
Doctors 'ignoring drugs warning'
Doctors are regularly prescribing two powerful psychiatric drugs to elderly dementia patients despite a safety warning in 2004, the BBC has found.
Antipsychotics May Improve Psychiatric Symptoms In Alzheimer's Disease
Main Category: Alzheimer's / Dementia Also Included In: Psychology / Psychiatry Article Date: 05 Jun 2008 - 5:00 PDT Psychiatric and behavioral symptoms associated with Alzheimer's disease-such as anger, ...
Short-Term Use of Antipsychotics in Older Adults With Dementia Linked to Serious Adverse Events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue ...
Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
Older adults with dementia who receive short-term courses of antipsychotic medications are more likely to be hospitalized or die than those who do not take the drugs, according to a report in the May 26 issue ...
Pharmacy fined following dispensing errors
"The errors that have occurred have been of great concern. "This was obviously not intended and we apologise for the distress and concern caused"
A pharmacy which mistakenly dispensed an anti-psychotic drug to a toddler has been fined $10,000 and had operational conditions imposed on it. via XtraMSN Real Estate
A new study, presented for the first time at an international psychiatric meeting, examined the time to relapse in patients with schizophrenia treated with risperidone long-acting injection or oral quetiapine. via MediLexicon
'CNS Generic Drugs: Prospects and Opportunities to 2012' Now Available
Research and Markets has announced the addition of CNS Generic Drugs: Prospects and Opportunities to 2012 to their offering. via Earth Times
Patients Treated with Risperidone Long-Acting Injection had a...
"This study provides compelling evidence that RLAI offers a significant benefit to people with schizophrenia in delaying the time to relapse"
Today, data from a new international study showed that patients treated with risperidone long-acting injection had a significantly longer time to relapse compared to patients treated with an oral atypical ... via Rehab Management
This Article is provided free of charge. Med Watch OTC cough medicine questions arise The FDA issued a Public Health Advisory concerning the use of over-the-counter cough/cold products in children and its ... via Nursing Center
Tier Status in Private Insurance Plans for Other Antipsychotic Drugs...
"For schizophrenia, bipolar disorder and major depression, psychiatrists will switch more Risperdal patients to generic risperidone than will PCPs"
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that when Janssen's Risperdal loses market exclusivity later this year in the United ... via Med Ad News
Supplemental New Drug Application For RISPERDAL(R) CONSTA(R)...
Alkermes, Inc. announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. , submitted a Supplemental New Drug Application for RISPERDAL CONSTA [ Long-Acting Injection] to the ... via MediLexicon
Court grants Teva generic Risperdal exclusivity
"We project Teva could record around $230 million (in sales) during its exclusivity period"
Teva Pharmaceutical Industries Ltd said on Friday a U.S. court granted a request that would give the Israeli company 180 days of exclusivity selling a generic version of widely used schizophrenia drug ... via Reuters
Begin
Your Free Case Review Fill out the following form or call 1-866-972-1500 24 hours a day, 7 days a week for a Free Case Review. |
What is Risperdal?
